Reasons a | % (n) |
---|---|
Drug development strategy | 31.4 (98) |
 Commercial or strategic decision | 26.9 (84) |
 Lack of funding | 2.2 (7) |
 Trial exemption | 2.2 (7) |
Trial planning | 32.1 (100) |
 Protocol issues | 13.1 (41) |
 Poor recruitment | 11.2 (35) |
 Inadequate supplies | 2.9 (9) |
 Study centre availability | 3.5 (11) |
 Experimental conditions failed to meet requirements | 1.3 (4) |
Trial conduct | 8.0 (25) |
 Good laboratory or clinical practice | 3.2 (10) |
 Poor compliance of volunteers | 0.6 (2) |
 Insufficient preparation | 3.5 (11) |
 Poor management ability of the principal investigator | 0.6 (2) |
Studied drug | 29.2 (91) |
 Futility/lack of efficacy | 22.4 (70) |
 Safety | 6.7 (21) |
No reasons given | 1.6 (5) |